Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Oktober 2008 08:30 ET | Quelle: Immunomedics, Inc.

Immunomedics Announces U.S. Patents Awarded for CD20 Antibody, Veltuzumab, and Reagents Used in Pretargeted Imaging and Therapies

MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious...
17. September 2008 11:31 ET | Quelle: Immunomedics, Inc.

Immunomedics Highlights Progress With Clinical Programs At R&D Day

MORRIS PLAINS, N.J., Sept. 17, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious...
08. September 2008 08:30 ET | Quelle: Immunomedics, Inc.

Immunomedics to Host R&D Day

MORRIS PLAINS, N.J., Sept. 8, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious...
28. August 2008 16:00 ET | Quelle: Immunomedics, Inc.

Immunomedics Announces Fiscal 2008 Results

MORRIS PLAINS, N.J., Aug. 28, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious...
01. August 2008 10:30 ET | Quelle: Immunomedics, Inc.

Results With Epratuzumab in Children With Acute Lymphoblastic Leukemia Published in Journal of Clinical Oncology

MORRIS PLAINS, N.J., Aug. 1, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious...
14. Juli 2008 08:30 ET | Quelle: Immunomedics, Inc.

Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications

MORRIS PLAINS, N.J., July 14, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) and Nycomed GmbH ("Nycomed") announced today that they have entered into a license and collaboration agreement...
18. Juni 2008 08:30 ET | Quelle: Immunomedics, Inc.

Immunomedics Announces Fractionated Pretargeted Radioimmunotherapy Improves Pancreatic Cancer Therapy in Animal Model

NEW ORLEANS, June 18, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases,...
17. Juni 2008 13:00 ET | Quelle: Immunomedics, Inc.

Immunomedics Develops Novel Radiotracer for Improved PET Imaging of Cancer

NEW ORLEANS, June 17, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases,...
16. Juni 2008 12:30 ET | Quelle: Immunomedics, Inc.

Immunomedics' Pretargeting Method May Improve Radioimmunoimaging of Cancer

NEW ORLEANS, La., June 16, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious...
09. Juni 2008 08:30 ET | Quelle: Immunomedics, Inc.

Immunomedics to Present At the Society of Nuclear Medicine 55th Annual Meeting

MORRIS PLAINS, N.J., June 9, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious...

Vorherige Seite